Dear partners and network, We are pleased to announce the publication of our second newsletter, a retrospective of the significant milestones and key scientific achievements of the Technological Research Platform virnext and its spin-offs throughout 2023. Access the newsletter here: https://lnkd.in/dF9si9Jw Thank you in advance for your support and confidence by sharing this newsletter with your network....
CNRS (Centre National de la Recherche Scientifique) biology has selected the research program of our International Associated Laboratory, RESPIVIR, France - Canada, as part of the International Research Program 2023 call (IRP). Involving Université Laval, Université Claude Bernard Lyon 1 and our Technology Research Platform Virnext, RESPIVIR was created between Manuel Rosa-Calatrava's team and that of Guy Boivin LVMC at the Centre de recherche du CHU de Québec-Université Laval to conduct...
On 13 December, this ceremony celebrated the contribution made by members of our university community to the reputation of Université Claude Bernard Lyon 1. The RESPIVIR France-Canada International Associate Laboratory, created with Laval University and involving Virnext, has been selected for the ETOILE2023 call for proposals, which supports excellence in research and innovation in line with the university's strategic priorities. This support from UCBL1 for the international dynamic of our...
We are delighted to welcome Gilles Devouassoux to the laboratory, with the shared ambition of strengthening our integrated fundamental, translational and clinical research activities, with a particular focus on bronchial inflammatory pathologies linked to respiratory viral infections. Gilles will bring to VirPath all his scientific and clinical expertise in pulmonary pathophysiology and his know-how in the implementation and coordination of international clinical trials for the development of bi...
This collaborative public-private research and development program aims to contribute to the management and prevention of microbiological and virological contamination risks, for better protection and quality of indoor air in confined spaces. Alongside their partners VirexpR, Conidia-Coniphy and IMéBIO, Virnext and the VirPath laboratory are committed to develop an ambitious technology offering that is unique in Europe. The aim of the GESPPAIR consortium is also to bring together other indus...
An excellent meeting with Bruno Marchand, Mayor of Quebec City, Carl Viel, CEO of Quebec International, and Guy Boivin, Professor at the Laval University’s Faculty of Medicine on the occasion of the 35th Jacques Cartier Meeting Days.  Fruitful discussions on the scientific and technological cooperation between our territories, focused on the study and control of emerging and re-emerging respiratory viruses, a major current health and economic challenge. The France-Canada Interna...
AIS Biotech, spun off from our R&D partnership with the Center for Research on Plant Macromolecules CERMAV, is the winner in the Health theme of the 25th edition of the i-Lab competition, organized by the Ministry of Higher Education, Research and Innovation in partnership with bpifrance. AIS Biotech project is to develop a new class of anti-infective biomedicines based on complex biosynthetic glycopolymers, is one of the 79 projects selected from among the 400 applications, which will be su...
Dear partners and network,The quarterly newsletter of Virnext is now available. This is a great opportunity to stay tuned and learn about the main scientific achievements and track record of the Technological Research Platform Virnext and its spin-offs.This first newsletter is devoted to a retrospective of the main value creations of our teams in 2022.Link to the newsletter: https://lnkd.in/dwxC7DZfPlease feel free to share this announcement. Thank you for your support and trust....
Survir is a public-private research and development program labeled by the Lyonbiopôle health competitiveness cluster and supported by the Regional Innovation Fund of the Auvergne-Rhône-Alpes Region and Bpifrance. With our partners AXO Science and EPIMOD, we are engaged in the last phase of this R&D booster 2021 partnership program which aims to develop an automated platform for the rapid characterization and quantification by imaging of a large panel of pathogenic respiratory viruses....
In this study, we report the efficacy, safety, and immunogenicity of BIMERVAX® in cynomolgus macaque model of SARS-CoV-2 we developed with Cynbiose. Prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, BIMERVAX® vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respirato...